Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas.

Ching-Yee Oliver Wong1, Joseph Thie, Kelly J Parling-Lynch

  • 1Nuclear Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA. owong@beaumont.edu

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|October 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lynch syndrome integrative epidemiology and genetics (LINEAGE): rationale for cohort design.

Familial cancer·2026
Same author

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Endometriosis in Carriers of a Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>: A Descriptive Analysis of a Large Multicentral <i>BRCA</i> Carrier Cohort.

Current oncology (Toronto, Ont.)·2025
Same author

The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>.

Current oncology (Toronto, Ont.)·2025
Same author

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.

Journal of the National Cancer Institute·2025
Same author

Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population.

Frontiers in oncology·2025

Optimizing the glucose sensitivity factor (g-value) in (18)F-FDG PET scans improves the classification of lymphoma grades. A g-value of -0.5 enhances the accuracy of distinguishing between indolent and aggressive lymphomas.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Accurate classification of lymphoma grades is crucial for treatment selection.
  • Standardized Uptake Value (SUV) in (18)F-FDG PET is influenced by glucose levels.
  • Normalization of SUV to glucose is necessary for reliable comparisons.

Purpose of the Study:

  • To determine the optimal glucose sensitivity factor (g-value) for normalizing SUV.
  • To identify the most discriminating SUV normalized to glucose for lymphoma grading.
  • To evaluate the impact of different g-values on classifying indolent versus aggressive lymphomas.

Main Methods:

  • (18)F-FDG PET scans from 102 patients were analyzed.
  • Maximum SUV was normalized to serum glucose ([Glc]) using various g-values (-3.0 to 0).

Related Experiment Videos

  • Discriminant analysis and g-plots were used to find the best g-value for classification, including analysis of extreme glucose conditions.

    • Main Results:

    • A g-value of -0.5 maximized the correct classification of lymphoma grades (up to 73%).
    • This g-value also provided optimal discrimination (92%) in patients with extreme glucose levels.
    • A threshold SUV(100) of 7.25 with g = -0.5 achieved 81% overall accuracy in identifying aggressive lymphomas.

    Conclusions:

    • Introducing a g-value as a degree of freedom improves metabolic discrimination between lymphoma grades.
    • (18)F-FDG PET with glucose-normalized SUV and an optimized g-value offers enhanced accuracy for lymphoma classification.
    • The findings support the use of a glucose sensitivity factor for more precise lymphoma grading.